Danske Bank A S Invests $94.51 Million in Boston Scientific Corporation $BSX

Danske Bank A S acquired a new stake in Boston Scientific Corporation (NYSE:BSX) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 968,085 shares of the medical equipment provider’s stock, valued at approximately $94,514,000. Danske Bank A S owned about 0.07% of Boston Scientific at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock valued at $13,497,294,000 after purchasing an additional 1,115,337 shares during the last quarter. State Street Corp increased its position in Boston Scientific by 1.1% during the second quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock worth $7,002,258,000 after buying an additional 713,379 shares during the last quarter. Synergy Asset Management LLC raised its stake in Boston Scientific by 3,493.0% in the third quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after buying an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC raised its stake in Boston Scientific by 39.5% in the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after buying an additional 14,700 shares during the period. Finally, Kepler Cheuvreux Suisse SA acquired a new stake in shares of Boston Scientific in the third quarter valued at approximately $26,955,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of research analysts recently weighed in on BSX shares. The Goldman Sachs Group set a $99.00 target price on Boston Scientific in a report on Thursday, February 5th. UBS Group cut their price target on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a report on Tuesday. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Mizuho lowered their price target on shares of Boston Scientific from $140.00 to $115.00 and set an “outperform” rating on the stock in a research report on Thursday, February 5th. Finally, Oppenheimer cut their price objective on shares of Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a report on Friday, January 16th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $107.32.

Boston Scientific Stock Up 2.0%

Shares of NYSE BSX opened at $71.19 on Wednesday. The company has a market cap of $105.64 billion, a price-to-earnings ratio of 36.70, a PEG ratio of 0.98 and a beta of 0.69. The company has a current ratio of 1.62, a quick ratio of 1.08 and a debt-to-equity ratio of 0.46. The stock has a 50-day moving average price of $81.42 and a two-hundred day moving average price of $92.71. Boston Scientific Corporation has a 12 month low of $67.56 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.78 by $0.02. Boston Scientific had a return on equity of 19.63% and a net margin of 14.44%.The firm had revenue of $5.29 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same period last year, the firm posted $0.70 earnings per share. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. As a group, analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Insider Transactions at Boston Scientific

In other news, CEO Michael F. Mahoney sold 160,901 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.50% of the company’s stock.

Boston Scientific News Roundup

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Analyst support remains, with UBS keeping a “buy” rating despite trimming its price target — this preserves broker confidence and highlights upside vs. current levels. Benzinga
• Positive Sentiment: Market writeups note the pullback may be overdone given solid recent financials (quarterly revenue and EPS strength and guidance), which supports a rebound narrative among value- and momentum-seeking investors. Is Boston Scientific Corp. (BSX) Pull Back Overdone as Financial Results Impress?
• Positive Sentiment: News summaries explaining why BSX outpaced the market today help attract short-term flows and algos reacting to momentum and analyst notes. Why Boston Scientific (BSX) Outpaced the Stock Market Today
• Neutral Sentiment: Some investor notices and law-firm solicitations are informational and can amplify trading volume even if they don’t change fundamentals immediately; these items tend to keep the stock volatile near-term. Boston Scientific Corporation (BSX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Multiple securities class-action filings and numerous law‑firm lead‑plaintiff solicitations allege disclosure problems around the U.S. Electrophysiology unit; this raises potential litigation risk, settlement exposure and near-term headline risk that can weigh on valuation. Boston Scientific Lawsuits Put Electrophysiology Outlook And Valuation In Focus
• Negative Sentiment: Numerous law firms (Rosen, Pomerantz, Faruqi, Bernstein Liebhard, Robbins Geller, etc.) have issued alerts about the May 4 lead-plaintiff deadline — repetitive alerts keep legal risk top of mind for investors and can suppress sentiment until the cases are resolved or dismissed. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors…

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.